Sugi Predict

Sugi Predict / Compounds / SCHEMBL5188552

SCHEMBL5188552

SCHEMBL5188552

O=[N+]([O-])c1ccc(Br)c2cccnc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 14/20 0.67
▸ ALDH1A1 P00352 11/20 0.67
▸ MEN1 O00255 9/20 0.67
▸ KMT2A Q03164 9/20 0.67
▸ LMNA P02545 4/20 0.67
▸ TDP1 Q9NUW8 7/20 0.58
▸ KDM4E B2RXH2 7/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.58
▸ HTT P42858 3/20 0.58
▸ CTSB P07858 2/20 0.58
▸ HSP90AA1 P07900 2/20 0.58
▸ OPRK1 P41145 2/20 0.58
▸ CASP6 P55212 2/20 0.58
▸ NPC1 O15118 1/20 0.58
▸ BRD4 O60885 1/20 0.58
▸ CHRM1 P11229 1/20 0.58
▸ DRD2 P14416 1/20 0.58
▸ ALOX12 P18054 1/20 0.58
▸ ADRA2B P18089 1/20 0.58
▸ ADRA2C P18825 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777337 1.00 MAPT (0.67) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL3189942 0.87 MAPT (0.67) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL29800698 0.87 ALDH1A1 (0.67) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL22120229 0.87 ALDH1A1 (0.67) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL31731538 0.87 MAPT (0.67) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL18979856 0.81 MAPT (0.55) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL8117697 0.80 PDE10A (0.60) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL8751507 0.80 MAPT (0.67) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL1552872 0.80 MAPT (1.00) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2469833 0.80 ALDH1A1 (1.00) MAPTALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025098509-A1 PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE 康百达（四川）生物医药科技有限公司 2025-05-15 — — WO disclosed
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 — — EP disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 — — CN disclosed
EP-3844159-B1 NOVEL PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-05-03 — — EP disclosed
CN-115666568-A Small molecule polymerase inhibitors 佐治亚州立大学研究基金会 2023-01-31 — — CN disclosed
US-20220411378-A1 SMALL MOLECULES POLYMERASE INHIBITORS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2022-12-29 — — US disclosed
US-20220363665-A1 QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2022-11-17 — — US disclosed
WO-2022199289-A1 NOVEL ANDROGEN RECEPTOR DEGRADER, PREPARATION METHOD, AND MEDICAL USE 中国药科大学 2022-09-29 — — WO disclosed
EP-4058023-A1 SMALL MOLECULES POLYMERASE INHIBITORS Georgia State University Research Foundation Inc. (US) 2022-09-21 — — EP disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed
EP-1313707-B1 QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS HOFFMANN LA ROCHE (CH) 2007-07-18 — — EP disclosed
US-7186840-B2 Quinoline derivatives as anti-inflammatory agents ROCHE PALO ALTO LLC (US) 2007-03-06 — — US disclosed
US-7049325-B2 Quinoline derivatives as anti-inflammatory agents SYNTEX (U.S.A.) LLC (US) 2006-05-23 — — US disclosed
US-20060084677-A1 Quinoline derivatives as anti-inflammatory agents BROKA CHRIS A 2006-04-20 — — US disclosed
CN-1199950-C Quinolene derivatives as anti-inflammation agents HOFFMANN LA ROCHE (CH) 2005-05-04 — — CN disclosed
CN-1466575-A Quinoline derivatives as anti-inflammatory agents - 2004-01-07 — — CN disclosed
EP-1313707-A1 QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-28 — — EP disclosed
US-20020082276-A1 Quinoline derivatives as anti-inflammatory agents SNYTEX (U.S.A.) LLC 2002-06-27 — — US disclosed
WO-2002012192-A1 QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084677-A1 Quinoline derivatives as anti-inflammatory agents NR5A2, PTGER4, IL5 MAPT 4551/4885ALDH1A1 1186/4885MEN1 4773/4885
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 MAPT 4801/4885ALDH1A1 3570/4885MEN1 2680/4885
US-20020082276-A1 Quinoline derivatives as anti-inflammatory agents CNR1, CNR2, PTGER4 MAPT 4539/4885ALDH1A1 633/4885MEN1 4796/4885
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 MAPT 441/4885ALDH1A1 1470/4885MEN1 2604/4885
US-20220363665-A1 QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE SSB, HLA-DRB1, NQO2 MAPT 3686/4885ALDH1A1 866/4885MEN1 98/4885
US-20220411378-A1 SMALL MOLECULES POLYMERASE INHIBITORS POLRMT, POLR1E, POLR2E MAPT 3370/4885ALDH1A1 3754/4885MEN1 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.